Abstract IA005: Emerging insights from the tebentafusp clinical program

Abstract

A majority of proteins that are specific for solid tumors are intracellular and thus can only be accessed by TCR-based therapeutics. Tebentafusp, a bispecific (gp100 x CD3) ImmTAC, is the first TCR therapeutic to demonstrate an overall survival benefit for any solid tumor.  In the Phase 3 IMCgp100-202 study in HLA-A*02:01+ adult patients with previously untreated metastatic uveal melanoma [NCT03070392], tebentafusp significantly improved overall survival (OS) and progression free survival compared to investigator’s choice  [HR 0.51 and HR 0.73, respectively]. Emerging insights from this first-in-class TCR therapeutic may be instructive to future development of other therapies in the same class.

Citation Format: David M. Berman. Emerging insights from the tebentafusp clinical program [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr IA005.